We then generated a PDX mouse model from the DLBCL patient sample (DFBL-18689) with reduced BCL-2 dependence, and subsequently treated the mice with venetoclax on a 5-day course per week for 3 weeks to ascertain susceptibility to venetoclax (Fig. 6B). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.